CRP and cardiac arrest: The IMICA trial included comatose patients resuscitated from out-of-hospital cardiac arrest and showed that tocilizumab significantly reduced the systemic inflammatory markers CRP and leukocyte counts as well as markers of myocardial injury such as CKMB and troponin levels [10].